NF1 tumor suppressor gene function: Narrowing the GAP

Cell

Volumn 104, Issue 4, 2001, Pages 593-604

  Cichowski, Karen ^a   Jacks, Tyler ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; NEUROFIBROMIN;

CARCINOGENESIS; ENZYME INACTIVATION; GENE MUTATION; HUMAN; NEUROFIBROMATOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCHWANN CELL; TUMOR SUPPRESSOR GENE;

EID: 0035936783     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(01)00245-8     Document Type: Review

References (83)

1. The Nf1 tumor suppressor regulates mouse skin wound healing, fibroblast proliferation, and collagen deposited by fibroblasts
2. Neurofibromatosis and cancer
3. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins
4. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients
5. Pathology of peripheral nerve
6. Chromosome band 9p21 is frequently altered in malignant peripheral nerve sheath tumors: Studies of CDKN2A and other genes of the pRB pathway
7. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells
8. Differential regulation of ras-GAP and neurofibromatosis gene product activities
9. Crosslinking of the surface immunoglobulin receptor in B lymphocytes induces a redistribution of neurofibromin but not p120-GAP
10. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues
11. Perineurium originates from fibroblasts: Demonstration in vitro with a retroviral marker
12. Experimental model of tumors associated with neurofibromatosis
13. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point
14. Mouse models of tumor development in neurofibromatosis type 1
15. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene
16. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis
17. Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models
18. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis
19. Pax3 and vertebrate development
20. The enigmatic perineurial cell and its participation in tumors and in tumorlike entities
21. Multiple cell origin of hereditary neurofibromas
22. Increased expression of the neurofibromatosis 1 (NF1) gene product, neurofibromin, in astrocytes in response to cerebral ischemia
23. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
24. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors
25. Requirement of Drosophila NF1 for activation of adenylyl cyclase by PACAP38-like neuropeptides
26. A neurofibromatosis-1-regulated pathway is required for learning in Drosophila
27. Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation
28. Regulation of Ras-GAP and the neurofibromatosis-1 gene product by eicosanoids
29. The hallmarks of cancer
30. Vascular system defects and neuronal apoptosis in mice lacking ras GTPase-activating protein
31. Neurofibromin GAP related domains (GRDs) restore normal growth in Nf1-/- cells
32. Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo
33. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1
34. Transgenic mouse model for neurocristopathy: Schwannomas and facial bone tumors
35. Origin and early development of Schwann cells
36. cAMP-dependent protein kinase A is required for Schwann cell growth: Interactions between the cAMP and neuregulin/tyrosine kinase pathways
37. Nf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: Reversion of some phenotypes by an inhibitor of farnesyl protein transferase
38. Making of a Schwann
39. p21 ras and phosphatidylinositol-3 kinase are required for survival of wild-type and NF1 mutant sensory neurons
40. Loss of NF1 allele in Schwann cells but not in fibroblasts derived from an NF1-associated neurofibroma
41. Allelic loss of the NF1 gene in NF1-associated plexiform neurofibromas
42. Mutation and cancer: Statistical study of retinoblastoma
43. Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas
44. Neurofibromin modulation of ras activity is required for normal endocardial-mesenchymal transformation in the developing heart
45. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma
46. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis
47. Loss of Apc+ in intestinal adenomas from Min mice
48. In vitro and in vivo effects of a farnesyl-transferase inhibitor on Nf1-deficient hematopoietic cells
49. Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation
50. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21
51. Neurocristopathy resembling neurofibromatosis type 1 in an NGF-SV40 transgenic line
52. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis
53. The retinoblastoma gene family: Cousins with overlapping interests
54. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation
55. Neurofibromin expression and astrogliosis in neurofibromatosis (type 1) brains
56. Cellular differentiation and expression of matrix genes in type 1 neurofibromatosis
57. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1
58. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects
59. Ras-mediated cell cycle arrest is altered by nuclear oncogenes to induce Schwann cell transformation
60. Neurofibromin-deficient fibroblasts fail to form perineurium in vitro
61. Identification of NF1 mutations in both alleles of a dermal neurofibroma
62. Cell signaling by receptor tyrosine kinases
63. Confirmation of a double-hit model for the NF1 gene in benign neurofibromas
64. Schwann cells harbor the somatic NF1 mutation in neurofibromas: Evidence of two different schwann cell subpopulations
65. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
66. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders
67. Angiogenic and invasive properties of neurofibroma Schwann cells
68. Tumor surveillance via the ARF-p53 pathway
69. A mouse model for the learning and memory deficits associated with neurofibromatosis type I
70. The neurofibroma in von Recklinghausen neurofibromatosis has a unicellular origin
71. Rescue of a Drosophila NF1 mutant phenotype by protein kinase A
72. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus
73. Loss of neurofibromin results in neurotrophin-independent survival of embryonic sensory and sympathetic neurons
74. Mouse tumor model for neurofibromatosis type 1
75. Type 1 neurofibromatosis gene: Identification of a large transcript disrupted in three NF1
76. Tumor suppressor genes
77. Pathology of the major peripheral nerve sheath neoplasms
78. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae
79. The neurofibromatosis type 1 gene encodes a protein related to GAP
80. Loss of NF1 alleles in phaeochromocytomas from patients with type I neurofibromatosis